You searched for "immunotherapy"
The future of bladder preservation for muscle-invasive bladder cancer
Localised muscle-invasive bladder cancer (MIBC) has historically been treated with radical cystectomy (RC), but bladder preservation therapy (BPT) has emerged as a credible and increasingly refined alternative. Early work by Herr in the 1980s demonstrated that radical transurethral resection of...ACP (Association for Continence Professionals) Annual Conference 2025
The main programme will be of interest to, Bladder and Bowel Nurses, Physiotherapists, Occupational Therapists, Urology Nurses, and Specialist Nurses as well as Doctors, Nurses and Allied Healthcare Professionals working within, or interested in Continence Care.
Save the orchid
In many urological cancers there is currently more and more inclination for organ-preserving surgery but in patients with germ cell tumours (GCT), radical orchidectomy remains the gold standard. Can we somehow save the testes? This study aims to summarise published...
Dilemma of second primary tumour
Long-term survival in localised prostate cancer (CaP) can be achieved with treatment by either radical prostatectomy (RP) or external beam radiotherapy (EBRT). The development of second primary tumour is poorly understood in such cases. This retrospective study included 84,397 cases...
Cryotherapy in prostate cancer
This review of the literature aims to summarise what is known in regards to outcomes in patients undergoing cryotherapy in a number of settings: whole gland, salvage and targeted focal therapy. It highlights that more prostate cancers are being diagnosed...PROSPACKS supports prostate cancer patients starting treatment in Scotland
Men across Scotland undergoing treatment for prostate cancer can benefit from new care and support packs thanks to a project by charity Prostate Scotland and long-term funder, the Grand Lodge of Scotland. PROSPACKS – tailored packs for men beginning radiotherapy,...Trials offering cytoreductive surgery for men with de novo synchronous metastatic prostate cancer
Life expectancy in men diagnosed with de novo synchronous metastatic hormone-sensitive prostate cancer (mHSPC) has risen to a median of 4.8 years with upfront systemic agents (such as docetaxel) in addition to standard androgen deprivation therapy (ADT) [1-3]. Within this...
